25 NOVEMBER 2010 NEW ZEALAND GAZETTE, No. 156 3899

New Zealand Sponsor: Celgene Limited
Manufacturers: Institute of Drug Technology (Aust) Limited, Boronia, Australia
Penn Pharmaceutical Services Limited, Tredegar, United Kingdom

Note: This consent is valid for two years from the date of publication of this notice and given subject to the following conditions:

• Thalidomide may only be prescribed by registered medical practitioners as defined in the Health Practitioners Competence Assurance Act 2003 and who are certified as competent by the Medical Council of New Zealand in the scope and practice of internal medicine.
• Celgene Limited will manage the risk management programme relating to the distribution and use of Thalomid.

Product: Thalomid
Active Ingredient: Thalidomide 100mg
Dosage Form: Capsule
New Zealand Sponsor: Celgene Limited
Manufacturers: Institute of Drug Technology (Aust) Limited, Boronia, Australia
Penn Pharmaceutical Services Limited, Tredegar, United Kingdom

Note: This consent is valid for two years from the date of publication of this notice and given subject to the following conditions:

• Thalidomide may only be prescribed by registered medical practitioners as defined in the Health Practitioners Competence Assurance Act 2003 and who are certified as competent by the Medical Council of New Zealand in the scope and practice of internal medicine.
• Celgene Limited will manage the risk management programme relating to the distribution and use of Thalomid.

Product: Thalomid
Active Ingredient: Thalidomide 150mg
Dosage Form: Capsule
New Zealand Sponsor: Celgene Limited
Manufacturers: Institute of Drug Technology (Aust) Limited, Boronia, Australia
Penn Pharmaceutical Services Limited, Tredegar, United Kingdom

Note: This consent is valid for two years from the date of publication of this notice and given subject to the following conditions:

• Thalidomide may only be prescribed by registered medical practitioners as defined in the Health Practitioners Competence Assurance Act 2003 and who are certified as competent by the Medical Council of New Zealand in the scope and practice of internal medicine.
• Celgene Limited will manage the risk management programme relating to the distribution and use of Thalomid.

Product: Thalomid
Active Ingredient: Thalidomide 200mg
Dosage Form: Capsule
New Zealand Sponsor: Celgene Limited
Manufacturers: Institute of Drug Technology (Aust) Limited, Boronia, Australia
Penn Pharmaceutical Services Limited, Tredegar, United Kingdom

Note: This consent is valid for two years from the date of publication of this notice and given subject to the following conditions:

• Thalidomide may only be prescribed by registered medical practitioners as defined in the Health Practitioners Competence Assurance Act 2003 and who are certified as competent by the Medical Council of New Zealand in the scope and practice of internal medicine.
• Celgene Limited will manage the risk management programme relating to the distribution and use of Thalomid.

Dated this 18th day of November 2010.

STEWART JESSAMINE, Acting Deputy Director-General, Population Health Directorate, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go8968

New Zealand Public Health and Disability Act 2000

Appointments/reappointments to District Health Boards

Pursuant to section 29(1)(b) of the New Zealand Public Health and Disability Act 2000 (“the NZPHD Act”) and notices given under section 28(2) of the Crown Entities Act 2004, I have appointed and reappointed members of the district health boards (“DHBs”) as listed in the table below.

Where individuals have chairperson or deputy chairperson listed in Column 1, I hereby appoint or reappoint those individuals to that office pursuant to clause 10(1) of Schedule 3 to the New Zealand Public Health and Disability Act 2000.

The appointment/reappointment of those persons as members takes effect on 6 December 2010.

The appointments/reappointments end on the date which appears in the relevant row of Column 3 of the table below.